• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis.

作者信息

Haroche Julien, Amoura Zahir, Charlotte Frédéric, Salvatierra Juan, Wechsler Bertrand, Graux Carlos, Brousse Nicole, Piette Jean-Charles

出版信息

Blood. 2008 Jun 1;111(11):5413-5. doi: 10.1182/blood-2008-03-148304.

DOI:10.1182/blood-2008-03-148304
PMID:18502845
Abstract
摘要

相似文献

1
Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis.甲磺酸伊马替尼用于血小板衍生生长因子受体-β阳性的 Erdheim-Chester 组织细胞增多症。
Blood. 2008 Jun 1;111(11):5413-5. doi: 10.1182/blood-2008-03-148304.
2
Response of histiocytoses to imatinib mesylate: fire to ashes.组织细胞增多症对甲磺酸伊马替尼的反应：化为灰烬。
J Clin Oncol. 2010 Nov 1;28(31):e633-6. doi: 10.1200/JCO.2010.29.9073. Epub 2010 Aug 23.
3
Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.血小板衍生生长因子受体作为骨肉瘤中预后标志物及甲磺酸伊马替尼治疗的靶点
Cancer. 2008 May 15;112(10):2119-29. doi: 10.1002/cncr.23437.
4
Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.胶质母细胞瘤中血小板衍生生长因子受体-α、-β、c-kit、c-abl和精氨酸酶蛋白的免疫组织化学分析：对甲磺酸伊马替尼治疗患者选择的潜在意义
J Neurooncol. 2006 Jan;76(2):105-9. doi: 10.1007/s11060-005-4570-9.
5
Erdheim-Chester disease harboring the BRAF V600E mutation.携带BRAF V600E突变的 Erdheim-Chester 病。
J Clin Oncol. 2012 Nov 10;30(32):e331-2. doi: 10.1200/JCO.2012.43.2260. Epub 2012 Sep 24.
6
Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura.简短报告：伊马替尼对一名血小板衍生生长因子受体阳性的胸膜恶性孤立性纤维性肿瘤患者的疗效
J Thorac Oncol. 2008 Aug;3(8):938-41. doi: 10.1097/JTO.0b013e3181803f08.
7
Molecular framework for response to imatinib mesylate in systemic sclerosis.系统性硬化症中对甲磺酸伊马替尼反应的分子框架
Arthritis Rheum. 2009 Feb;60(2):584-91. doi: 10.1002/art.24221.
8
Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion.成功应用酪氨酸激酶抑制剂治疗一例伴有EBF1-PDGFRB融合基因的难治性B细胞前体急性淋巴细胞白血病
Haematologica. 2013 Nov;98(11):e146-8. doi: 10.3324/haematol.2013.095372.
9
[Hypereosinophilic syndrome and Löffler endocarditis caused by FIP1L-PDGFRA rearrangement: effectiveness of imatinib mesylate therapy].[FIP1L-PDGFRA重排所致嗜酸性粒细胞增多综合征和吕弗勒心内膜炎：甲磺酸伊马替尼治疗的有效性]
Med Clin (Barc). 2007 Jun 23;129(4):159. doi: 10.1157/13107495.
10
The challenge of choosing appropriate end points in single-arm phase II studies of rare diseases.在罕见病单臂II期研究中选择合适终点的挑战。
J Clin Oncol. 2012 Mar 20;30(9):896-8. doi: 10.1200/JCO.2011.40.6942. Epub 2012 Feb 13.

引用本文的文献

1
Recent advances in therapeutic strategies of Erdheim-Chester disease.Erdheim-Chester病治疗策略的最新进展
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun;398(6):6407-6428. doi: 10.1007/s00210-024-03769-2. Epub 2025 Jan 21.
2
[Mutation pedigree and treatment selection of Erdheim-Chester disease].[ Erdheim-Chester病的突变谱系与治疗选择 ]
Zhonghua Xue Ye Xue Za Zhi. 2023 Oct 14;44(10):876-880. doi: 10.3760/cma.j.issn.0253-2727.2023.10.019.
3
An Unusual Case of Erdheim Chester Disease (ECD) with Knee Pain: A Case Report.
厄德海姆-切斯特病（ECD）伴膝关节痛 1 例：病例报告
Medicina (Kaunas). 2023 Jul 12;59(7):1288. doi: 10.3390/medicina59071288.
4
Erdheim-Chester Disease of the Breast: First Review and First Case of Isolated Severe Gynecomastia.乳腺 Erdheim-Chester 病：首例综述及首例孤立性重度男性乳房发育病例
Diagnostics (Basel). 2023 Mar 25;13(7):1239. doi: 10.3390/diagnostics13071239.
5
Genetics and clinical phenotype of Erdheim-Chester disease: A case report of constrictive pericarditis and a systematic review of the literature.Erdheim-Chester病的遗传学与临床表型：缩窄性心包炎病例报告及文献系统综述
Front Cardiovasc Med. 2022 Aug 11;9:876294. doi: 10.3389/fcvm.2022.876294. eCollection 2022.
6
Results of TETimaX Trial of Langerhans Cell Histiocytosis Treatment and Perspectives on the Role of Imatinib Mesylate in the Era of MAPK Signaling.朗格汉斯细胞组织细胞增多症治疗的TETimaX试验结果及甲磺酸伊马替尼在MAPK信号传导时代作用的展望
Biomedicines. 2021 Nov 24;9(12):1759. doi: 10.3390/biomedicines9121759.
7
Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.维莫非尼在携带 BRAF V600E 突变的儿童朗格汉斯细胞组织细胞增生症中提供了快速而显著的临床应答，但使用游离循环细胞 DNA 的 ddPCR 并不能消除低水平的微小残留病灶。
Int J Hematol. 2021 Dec;114(6):725-734. doi: 10.1007/s12185-021-03205-8. Epub 2021 Aug 12.
8
Dasatinib induces a dramatic response in a child with refractory juvenile xanthogranuloma with a novel MRC1-PDGFRB fusion.达沙替尼诱导 1 例难治性幼年黄色肉芽肿患儿产生戏剧性反应，该患儿存在新型 MRC1-PDGFRB 融合。
Blood Adv. 2020 Jul 14;4(13):2991-2995. doi: 10.1182/bloodadvances.2020001890.
9
Erdheim-Chester Disease With Extensive Pericardial Involvement: A Case Report and Systematic Review.广泛心包受累的 Erdheim-Chester 病：一例报告及系统评价
Cardiol Res. 2020 Apr;11(2):118-128. doi: 10.14740/cr1025. Epub 2020 Mar 10.
10
A Rare Case of Erdheim-Chester Disease (Non-Langerhans Cell Histiocytosis) with Concurrent Langerhans Cell Histiocytosis: A Diagnostic and Therapeutic Challenge.一例罕见的 Erdheim-Chester 病（非朗格汉斯细胞组织细胞增多症）合并朗格汉斯细胞组织细胞增多症：诊断与治疗挑战
Case Rep Hematol. 2018 May 16;2018:7865325. doi: 10.1155/2018/7865325. eCollection 2018.